Cellectis to Present Allogeneic CAR T-Cell Immunotherapy Data at EHA Meeting

Gene-editing company Cellectis announced it will present preclinical data on its allogeneic CAR T-cell immunotherapy programs at the European Hematology Association (EHA) Annual Meeting. The conference is scheduled to take place in Vienna, Austria, from June 11th to 14th, 2015.

The company, which utilizes proprietary technologies for the development of CAR T-cell products in adoptive immunotherapy for cancer, will feature its research findings in two oral presentations and one poster presentation. The presented data will focus on Cellectis' engineered allogeneic CAR T-cells.

Adoptive immunotherapy involves modifying a patient's immune cells to target and destroy cancer. Allogeneic cells are derived from healthy donors and can potentially be used in multiple patients, contrasting with autologous therapies that are patient-specific.

Cellectis aims to develop CAR T-cell products using its gene-editing platforms. The presentations at the EHA meeting are expected to provide insights into the progress and potential of these programs. The company is listed on Alternext (ALCLS) and the Nasdaq Global Market (CLLS).